A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
R-Pharm
Oscotec Inc.
University of Southern California
Memorial Sloan Kettering Cancer Center
Memgen, Inc.
Thomas Jefferson University
Dana-Farber Cancer Institute
University of Cincinnati
Gustave Roussy, Cancer Campus, Grand Paris
Ohio State University Comprehensive Cancer Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Groupe Oncologie Radiotherapie Tete et Cou
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Massachusetts General Hospital
Dana-Farber Cancer Institute
University of Arizona
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center